These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24632142)

  • 1. Reexamination of aspartoacylase: is this human enzyme really a glycoprotein?
    Wang Q; Viola RE
    Arch Biochem Biophys; 2014 Apr; 548():66-73. PubMed ID: 24632142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease.
    Le Coq J; An HJ; Lebrilla C; Viola RE
    Biochemistry; 2006 May; 45(18):5878-84. PubMed ID: 16669630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.
    Herga S; Berrin JG; Perrier J; Puigserver A; Giardina T
    FEBS Lett; 2006 Oct; 580(25):5899-904. PubMed ID: 17027983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
    Bitto E; Bingman CA; Wesenberg GE; McCoy JG; Phillips GN
    Proc Natl Acad Sci U S A; 2007 Jan; 104(2):456-61. PubMed ID: 17194761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and preliminary characterization of brain aspartoacylase.
    Moore RA; Le Coq J; Faehnle CR; Viola RE
    Arch Biochem Biophys; 2003 May; 413(1):1-8. PubMed ID: 12706335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of aspartoacylase: implications for Canavan disease.
    Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
    Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
    Kaul R; Gao GP; Balamurugan K; Matalon R
    Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective.
    Wijayasinghe YS; Pavlovsky AG; Viola RE
    Biochemistry; 2014 Aug; 53(30):4970-8. PubMed ID: 25003821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine aspartoacylase: cloning, expression and comparison with the human enzyme.
    Namboodiri MA; Corigliano-Murphy A; Jiang G; Rollag M; Provencio I
    Brain Res Mol Brain Res; 2000 May; 77(2):285-9. PubMed ID: 10837925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between enzyme properties and disease progression in Canavan disease.
    Zano S; Wijayasinghe YS; Malik R; Smith J; Viola RE
    J Inherit Metab Dis; 2013 Jan; 36(1):1-6. PubMed ID: 22850825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new T677C mutation of the aspartoacylase gene encodes for a protein with no enzymatic activity.
    Di Pietro V; Gambacurta A; Amorini AM; Finocchiaro A; D'Urso S; Ceccarelli L; Tavazzi B; Giardina B; Lazzarino G
    Clin Biochem; 2008 May; 41(7-8):611-5. PubMed ID: 18280251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease.
    Kocak A; Yildiz M
    J Mol Graph Model; 2017 Jun; 74():44-53. PubMed ID: 28349879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-glycosylation influences the latency and catalytic properties of mammalian purple acid phosphatase.
    Wang Y; Norgård M; Andersson G
    Arch Biochem Biophys; 2005 Mar; 435(1):147-56. PubMed ID: 15680916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canavan disease: molecular basis of aspartoacylase deficiency.
    Kaul R; Gao GP; Balamurugan K; Matalon R
    J Inherit Metab Dis; 1994; 17(3):295-7. PubMed ID: 7528829
    [No Abstract]   [Full Text] [Related]  

  • 15. Cloning and characterization of a novel amidase from Paracoccus sp. M-1, showing aryl acylamidase and acyl transferase activities.
    Shen W; Chen H; Jia K; Ni J; Yan X; Li S
    Appl Microbiol Biotechnol; 2012 May; 94(4):1007-18. PubMed ID: 22101784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the N-glycosylation sites on recombinant bovine CD38 expressed in Pichia pastoris: their impact on enzyme stability and catalytic activity.
    Muller-Steffner H; Kuhn I; Argentini M; Schuber F
    Protein Expr Purif; 2010 Apr; 70(2):151-7. PubMed ID: 19818407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue.
    Le Coq J; Pavlovsky A; Malik R; Sanishvili R; Xu C; Viola RE
    Biochemistry; 2008 Mar; 47(11):3484-92. PubMed ID: 18293939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Unalp A; Altiok E; Uran N; Oztürk A; Yüksel S
    J Trop Pediatr; 2008 Jun; 54(3):208-10. PubMed ID: 17999961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Directed evolution and structural analysis of N-carbamoyl-D-amino acid amidohydrolase provide insights into recombinant protein solubility in Escherichia coli.
    Jiang S; Li C; Zhang W; Cai Y; Yang Y; Yang S; Jiang W
    Biochem J; 2007 Mar; 402(3):429-37. PubMed ID: 17121498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.